Early Symptoms of Alzheimer's Disease

At Risk For Alzheimer's

The main purpose of this study is to compare donanemab to aducanumab on amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer’s disease.

A Study of Donanemab (LY3002813) in Participants with Early Alzheimer’s Disease (TRAILBLAZER-ALZ 2)

The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer’s disease and to validate video scale assessments.

A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)

Mild Cognitive Impairment

Mild Alzheimer's

Moderate Alzheimer's

The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with AD.  The study has two parts:  Part A - Healthy participants will receive LY3372993 or placebo. Part A will last up to  17 weeks and Part B - Participants with AD will receive LY3372993 or placebo. Part B will last about 317 days.

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

This study involves repeated doses of LY3303560 given by injection for 25 weeks. The study will examine how safe repeated doses of LY3303560 are, whether they cause side effects in participants with mild cognitive impairment or Alzheimer's Disease, and how LY3303560 is handled by the body and acts in the body.

A Study of LY3303560 in Participants with Mild Cognitive Impairment or Alzheimer's Disease

The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560, administered either intravenously or subcutaneously, in both healthy participants and patients with Alzheimer's disease. Side effects and laboratory results will be monitored.

A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

The purpose of this study is to evaluate the effect of LY3002813 on brain scans, evaluate the safety of LY3002813 by looking at adverse events (side effects) and to look at the effect of LY3002813 on the body. The study is for research purposes only and is not intended to treat any medical condition.

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

The purpose of this study is to evaluate the safety and tolerability of LY3372993 in participants with AD and  and healthy participants who are of first-generation Japanese origin.

A Study of LY3372993 in Participants With Alzheimer’s Disease (AD) and Healthy Participants

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease.

Search Match Terms (4)

Recruiting

A Study of LY3372993 in Participants With Alzheimer’s Disease (AD) and Healthy Participants

Search Match Terms:

Early Symptoms of Alzheimer's Disease

|

Moderate Alzheimer's

|

Mild Alzheimer's

Enter your postal codeto see sites near you

View Trial

Recruiting

A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Search Match Terms:

Early Symptoms of Alzheimer's Disease

|

At Risk For Alzheimer's

Enter your postal codeto see sites near you

View Trial

Recruiting

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease (PROSPECT-ALZ)

Search Match Terms:

Early Symptoms of Alzheimer's Disease

Enter your postal codeto see sites near you

View Trial

Not the right fit? Sign up to receive updates on new trials.

Active not recruiting

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

Search Match Terms:

Early Symptoms of Alzheimer's Disease

|

At Risk For Alzheimer's

Enter your postal codeto see sites near you

View Trial

Active not recruiting

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

Search Match Terms:

Early Symptoms of Alzheimer's Disease

Enter your postal codeto see sites near you

View Trial

Active not recruiting

A Study of Donanemab (LY3002813) in Participants with Early Alzheimer’s Disease (TRAILBLAZER-ALZ 2)

Search Match Terms:

Early Symptoms of Alzheimer's Disease

Enter your postal codeto see sites near you

View Trial

Active not recruiting

A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

Search Match Terms:

Early Symptoms of Alzheimer's Disease

Enter your postal codeto see sites near you

View Trial

Active not recruiting

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)

Search Match Terms:

At Risk For Alzheimer's

Enter your postal codeto see sites near you

View Trial

Enter your postal code
to see sites near you

Enter your postal code
to see sites near you

Enter your postal code
to see sites near you

Enter your postal code
to see sites near you

Enter your postal code
to see sites near you

Enter your postal code
to see sites near you

Enter your postal code
to see sites near you

Enter your postal code
to see sites near you